588 assets in Acute Myeloid Leukemia

Therapeutic assets addressing Acute Myeloid Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Eras-601 Acute Myeloid Leukemia	Erasca, Inc.	P1/2	CC (40)
Expanded Haploidentical Nk Cells Acute Myeloid Leukemia	Belarusian Research Center for Pediatric Oncology, Hematology and Immunology	P1/2	CC (40)
Ex-Vivo Expanded Γδ T Cell Infusion Acute Myeloid Leukemia	Chinese PLA General Hospital	P1/2	CC (40)
imm01 Acute Myeloid Leukemia	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1/2	CC (40)
Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3)] And Anti-[Homo Sapiens Cd274 (Programmed Cell Death 1 Ligand 1, Pdl1, Pd-L1, B7 Homolog 1, B7H1, B7-H1, Pdcd1Lg1)], Humanized Monoclonal Antibody, Bispecific, Bivalent Acute Myeloid Leukemia	Mabwell (Shanghai) Bioscience Co., Ltd.	P1/2	CC (40)
Inobrodib Acute Myeloid Leukemia	CellCentric Ltd.	P1/2	CC (40)
Lanraplenib Acute Myeloid Leukemia	Kronos Bio	P1/2	CC (40)
Magrolimab Acute Myeloid Leukemia	Novartis Pharmaceuticals	P3	CC (40)
Mezigdomide Acute Myeloid Leukemia	Memorial Sloan Kettering Cancer Center	P1/2	CC (40)
Mobinitinib Acute Myeloid Leukemia	Ellipses Pharma	P1/2	CC (40)
muc1/cll1/cd33/cd38/cd56/cd123-specific gene-engineered t cells Acute Myeloid Leukemia	Shenzhen Geno-Immune Medical Institute	P1/2	CC (40)
Muc-1 Peptide Vaccine Acute Myeloid Leukemia	Shenzhen Geno-Immune Medical Institute	P1/2	CC (40)
Ntla-5001 Acute Myeloid Leukemia	Intellia Therapeutics	P1/2	CC (40)
Petiveria Alliacea Preparation Acute Myeloid Leukemia	Hospital Universitario San Ignacio	P1/2	CC (40)
rp7214 Acute Myeloid Leukemia	Rhizen Pharmaceuticals SA	P1/2	CC (40)
sar443579 Acute Myeloid Leukemia	Sanofi	P1/2	CC (40)
Siremadlin Acute Myeloid Leukemia	Novartis Pharmaceuticals	P1/2	CC (40)
Sulfasalazine Acute Myeloid Leukemia	Assistance Publique - Hôpitaux de Paris	P1/2	CC (40)
Syhx1903 Acute Myeloid Leukemia	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P1/2	CC (40)
Tamibarotene Acute Myeloid Leukemia	Syros Pharmaceuticals	P2	CC (40)
Teclistamab Acute Myeloid Leukemia	CellCentric Ltd.	P1/2	CC (40)
Tgrx-814 Acute Myeloid Leukemia	Shenzhen TargetRx Co., Ltd.	P1/2	CC (40)
Tozinameran Acute Myeloid Leukemia	Assistance Publique - Hôpitaux de Paris	P1/2	CC (40)
tqb3454 Acute Myeloid Leukemia	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1/2	CC (40)
Universal Donor Natural Killer Cells Acute Myeloid Leukemia	Nationwide Children's Hospital	P1/2	CC (40)
White Blood Cells/Granulocytes Acute Myeloid Leukemia	University of Manchester	P1/2	CC (40)
Adgre2 Car-T Acute Myeloid Leukemia	Zhejiang University	P1	C (39)
Apvo436 Acute Myeloid Leukemia	Aptevo Therapeutics	P1	C (39)
Autologous Car123 T Lymphocytes Acute Myeloid Leukemia	Institute of Hematology and Blood Transfusion, Czech Republic	Early P1	C (39)
cd33-car-t cell infusion Acute Myeloid Leukemia	Qi deng	P1	C (39)
Cer-1236 Acute Myeloid Leukemia	CERo Therapeutics Holdings, Inc.	P1	C (39)
cg009301 for Acute Myeloid Leukemia	Cullgen (Shanghai),Inc	P1	C (39)
ct101a Acute Myeloid Leukemia	Zhejiang University	P1	C (39)
fd-001 Acute Myeloid Leukemia	Chengdu FenDi Pharmaceutical Co., Ltd.	P1	C (39)
jd123 Acute Myeloid Leukemia	Peking University People's Hospital	Early P1	C (39)
Jnj-74856665 Acute Myeloid Leukemia	Janssen Research & Development, LLC	P1	C (39)
Lispro-Ph20 Component Rhuph20 Acute Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P1	C (39)
nk520 Acute Myeloid Leukemia	Base Therapeutics (Shanghai) Co., Ltd.	Early P1	C (39)
Padnarsertib Acute Myeloid Leukemia	University of Colorado, Denver	P1	C (39)
qh101 Acute Myeloid Leukemia	Anhui Provincial Hospital	P1	C (39)
qn-023a Acute Myeloid Leukemia	Zhejiang University	P1	C (39)
qn-030a Acute Myeloid Leukemia	Zhejiang University	P1	C (39)
Sabatolimab Acute Myeloid Leukemia	M.D. Anderson Cancer Center	P2	C (39)
Tsc-100 Acute Myeloid Leukemia	TScan Therapeutics, Inc.	P1	C (39)
Tsc-101 Acute Myeloid Leukemia	TScan Therapeutics, Inc.	P1	C (39)
Wu-Nk-101 Acute Myeloid Leukemia	Wugen, Inc.	P1	C (39)
Xzb-0004 Acute Myeloid Leukemia	Xuanzhu Biopharmaceutical Co., Ltd.	P1	C (39)
Ex-Vivo Expanded Allogeneic Γδ T Cells Acute Myeloid Leukemia	Institute of Hematology & Blood Diseases Hospital, China	Early P1	C (38)
Hema-Neotil01 Acute Myeloid Leukemia	The First Affiliated Hospital of Soochow University	Early P1	C (38)
Human Derived Anti-Ci135 Car-T Acute Myeloid Leukemia	Hrain Biotechnology Co., Ltd.	Early P1	C (38)

Showing 401 to 450 of 588 assets

PreviousPage 9 of 12Next